Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update

Go back to Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update
(NASDAQ: GRCL) Delayed: 11.05 +1.30 (13.33%)
Previous Close $9.75    52 Week High
Open $10.12    52 Week Low
Day High $11.05    P/E N/A 
Day Low $9.82    EPS
Volume 62,109